{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumors+and+Advanced+Endometrial+Cancer&page=4", "query": { "condition": "Solid Tumors and Advanced Endometrial Cancer", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 180, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumors+and+Advanced+Endometrial+Cancer&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumors+and+Advanced+Endometrial+Cancer&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T15:12:32.554Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07038369", "title": "A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Breast Cancer", "Breast Carcinoma", "Breast Neoplasms", "ER Positive Breast Cancer", "Cervical Cancers", "Cervical Neoplasms", "Cervical Carcinoma", "Triple Negative Breast Cancer", "Gynecologic Cancers", "Gynecologic Neoplasm", "Endometrial Cancer", "Endometrial Neoplasm", "Endometrial Carcinoma (EC)", "Fallopian Cancer", "Ovarian Carcinoma", "Ovarian Cancer", "Ovarian Neoplasms", "Prostate Cancers", "Prostate Carcinoma", "Solid Tumors", "Neoplasms", "Neoplasms by Site", "Breast Diseases", "Uterine Neoplasms", "Genital Neoplasms, Female", "Urogenital Neoplasms" ], "interventions": [ { "name": "ATV-1601", "type": "DRUG" }, { "name": "ATV-1601 + Fulvestrant", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Atavistik Bio, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2025-07-29", "completion_date": "2029-01-31", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-10-08T15:12:32.554Z", "location_count": 5, "location_summary": "Los Angeles, California • Lake Mary, Florida • Boston, Massachusetts + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07038369" }, { "nct_id": "NCT06974110", "title": "Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor", "Endometrial Cancer", "MSI-H Cancer", "Colorectal Cancer", "Gastric Cancer", "dMMR Cancer" ], "interventions": [ { "name": "MOMA-341", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Immunotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MOMA Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2025-07-16", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-10-08T15:12:32.554Z", "location_count": 9, "location_summary": "Phoenix, Arizona • San Diego, California • Tampa, Florida + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06974110" }, { "nct_id": "NCT06270706", "title": "A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumor" ], "interventions": [ { "name": "PLN-101095", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pliant Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2023-08-30", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-08T15:12:32.554Z", "location_count": 16, "location_summary": "New Haven, Connecticut • Atlanta, Georgia • Grand Rapids, Michigan + 11 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "East Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06270706" }, { "nct_id": "NCT04925284", "title": "Study of XB002 in Subjects With Solid Tumors (JEWEL-101)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Cervical Cancer", "SCCHN", "Pancreatic Cancer", "Esophageal SCC", "Metastatic Castration-resistant Prostate Cancer", "Triple Negative Breast Cancer", "Hormone Receptor-positive Breast Cancer", "Epithelial Ovarian Cancer", "Endometrial Cancer", "Tissue Factor-Expressing Solid Tumors" ], "interventions": [ { "name": "XB002", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 269, "start_date": "2021-06-07", "completion_date": "2025-03-10", "has_results": false, "last_update_posted_date": "2025-04-04", "last_synced_at": "2026-10-08T15:12:32.554Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04925284" }, { "nct_id": "NCT07044336", "title": "Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Cancer", "Malignant Solid Tumour" ], "interventions": [ { "name": "Puxitatug Samrotecan", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 800, "start_date": "2025-08-01", "completion_date": "2029-07-17", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-08T15:12:32.554Z", "location_count": 69, "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 60 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07044336" }, { "nct_id": "NCT04196257", "title": "BP1001-A in Patients With Advanced or Recurrent Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Carcinoma, Ovarian Epithelial", "Fallopian Tube Neoplasms", "Endometrial Cancer", "Peritoneal Cancer", "Solid Tumor" ], "interventions": [ { "name": "BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)", "type": "DRUG" }, { "name": "BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bio-Path Holdings, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2022-08-19", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2025-03-07", "last_synced_at": "2026-10-08T15:12:32.554Z", "location_count": 4, "location_summary": "Silver Spring, Maryland • Detroit, Michigan • Dallas, Texas + 1 more", "locations": [ { "city": "Silver Spring", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04196257" }, { "nct_id": "NCT05856981", "title": "Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Metastatic Solid Tumor", "Refractory Cancer", "CRC, Colorectal Cancer", "RCC, Clear Cell Adenocarcinoma", "NSCLC (Advanced Non-small Cell Lung Cancer)", "Endometrial Cancer" ], "interventions": [ { "name": "ADU-1805", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sairopa B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2023-04-03", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2025-12-17", "last_synced_at": "2026-10-08T15:12:32.554Z", "location_count": 4, "location_summary": "Detroit, Michigan • St Louis, Missouri • Canton, Ohio + 1 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Canton", "state": "Ohio" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05856981" }, { "nct_id": "NCT02611024", "title": "Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Glioblastoma", "Soft Tissue Sarcoma (Excluding GIST)", "Endometrial Carcinoma", "Epithelial Ovarian Carcinoma", "Mesothelioma", "Gastroenteropancreatic Neuroendocrine Tumor", "SCLC", "Gastric Carcinoma", "Pancreatic Adenocarcinoma", "Colorectal Carcinoma", "Neuroendocrine Tumors" ], "interventions": [ { "name": "Lurbinectedin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PharmaMar", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 316, "start_date": "2016-05-06", "completion_date": "2025-07-01", "has_results": false, "last_update_posted_date": "2025-07-09", "last_synced_at": "2026-10-08T15:12:32.554Z", "location_count": 4, "location_summary": "Santa Monica, California • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02611024" }, { "nct_id": "NCT05001282", "title": "A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Ovarian Neoplasms", "Ovarian Carcinoma", "Endometrial Cancer", "Ovary Cancer", "Ovary Neoplasm", "Ovary Disease", "Ovary Metastasis", "Ovarian Diseases", "Ovarian Cancer Stage", "Ovarian Epithelial Cancer", "Ovarian Adenocarcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Neoplasm Epithelial", "Ovarian Cancer Recurrent", "Endometrial Diseases", "Endometrial Adenocarcinoma", "Endometrial Carcinosarcoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrioid Adenocarcinoma", "Endometrial Neoplasms", "Endometrial Cancer Recurrent", "Endometrioid Tumor", "Fallopian Tube Cancer", "Peritoneal Cancer" ], "interventions": [ { "name": "ELU001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elucida Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2021-09-13", "completion_date": "2024-06-07", "has_results": false, "last_update_posted_date": "2024-08-07", "last_synced_at": "2026-10-08T15:12:32.554Z", "location_count": 18, "location_summary": "Phoenix, Arizona • Fullerton, California • Jacksonville, Florida + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Margate", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05001282" }, { "nct_id": "NCT06276491", "title": "Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Endometrial Cancer", "Germ Cell Tumor", "Testicular Germ Cell Tumor", "Ovarian Germ Cell Tumor" ], "interventions": [ { "name": "XmAb541", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 282, "start_date": "2024-04-04", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-08T15:12:32.554Z", "location_count": 17, "location_summary": "Duarte, California • Palo Alto, California • San Francisco, California + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06276491" } ] }